Symbols

OMER

Omeros·NASDAQ

--(--)

OMER fundamentals

OMER Q4 2025 Earnings Preview

Omeros (OMER) expects to report earnings on Mar 31, 2026, with estimated revenue of 0 (YoY --), and EPS at -0.57 (YoY -5.56%).

Revenue estimate / YoY

EPS estimate / YoY

-0.57

-5.56%

Report date

Mar 31, 2026

OMER Earnings Call Summary for Q4,2025

$2.1B Deal Milestone: Zaltenibart sale to Novo Nordisk includes $240M upfront, $410M development milestones, and high-teens royalties.
YARTEMLEA Launch Success: 30% of top 80 transplant centers have formulary approval; 24-hour drug delivery meets urgent patient needs.
Financial Strength: $171.8M cash, debt-free except $70.8M convertible notes. YARTEMLEA expected to be self-sustaining in 2026, cash flow positive by 2027.
Clinical Impact: First treatment for TA-TMA with no safety restrictions, reducing infection risks vs. C5 inhibitors.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Omeros (OMER) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Omeros (OMER)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Omeros (OMER)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Omeros (OMER)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown